FindTrial
Sign In

Low-Dose Rocuronium with Sugammadex Reversal in Bronchoscopy: A Randomized, Double-Blind, Controlled Trial

Low-Dose Rocuronium with Sugammadex Reversal in Bronchoscopy: A Randomized, Double-Blind, Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116808
Enrollment
Unknown
Registered
2026-01-15
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchoscopy

Interventions

Intervention group:Remifentanil, propofol, and rocuronium were administered intravenously
Control group:Remifentanil, propofol were administered intravenously

Sponsors

Jiangsu Taizhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA class I or II; 2. Age 18-65 years; 3. BMI 18-29 kg/m².

Exclusion criteria

Exclusion criteria: 1. Abnormal cardiac, hepatic, or renal function; 2. Fluid-electrolyte or acid-base imbalances; 3. History of neuromuscular disorders; 3. Preoperative use of drugs affecting neuromuscular transmission.

Design outcomes

Primary

MeasureTime frame
Cough Incidence;—

Secondary

MeasureTime frame
Additional dose of propofol;Additional dose of remifentanil;—

Countries

China

Contacts

Public ContactDapeng Yu

Taizhou People’s Hospital

1761059177@qq.com+86 180 5106 2521

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026